Standout Papers

Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection 2013 2026 2017 2021 581
  1. Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection (2013)
    Sharon Walmsley, Antonio Antela et al. New England Journal of Medicine

Immediate Impact

1 by Nobel laureates 4 from Science/Nature 62 standout
Sub-graph 1 of 19

Citing Papers

Potential Clinical and Economic Impacts of Cutbacks in the President’s Emergency Plan for AIDS Relief Program in South Africa
2025 Standout
Mechanisms of long COVID and the path toward therapeutics
2024 Standout
2 intermediate papers

Works of Dan Duiculescu being referenced

Lipid Levels and Changes in Body Fat Distribution in Treatment-Naive, HIV-1–Infected Adults Treated With Rilpivirine or Efavirenz for 96 Weeks in the ECHO and THRIVE Trials
2014
Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection
2013 Standout

Author Peers

Author Last Decade Papers Cites
Dan Duiculescu 621 794 224 22 931
Aza Rakhmanova 566 774 322 40 952
A. Gregory DiRienzo 624 704 116 29 1.1k
Winai Ratanasuwan 583 790 248 37 932
Gary Richmond 702 725 203 26 1.1k
Edmund Wilkins 435 587 146 24 755
Peter Gute 669 844 294 35 1.1k
José Ramón Santos 481 599 171 40 778
Douglas J. Manion 764 892 165 10 1.0k
Joseph J. Eron 721 947 181 28 1.1k
Amy Cutrell 572 737 220 18 1.0k

All Works

Loading papers...

Rankless by CCL
2026